Study STX-721-101 is an open label, Phase 1/2 study evaluating the safety, tolerability,pharmacokinetic (PK) exposure, and preliminary antitumor activity of STX-721 inparticipants with non-small cell lung cancer (NSCLC) carrying EGFR/HER2 exon 20 insertion(ex20ins) mutations.
The STX-721-101 study is a phase 1/2, open-label study to evaluate the safety, tolerability, pharmacokinetic (PK) exposure and preliminary antitumor activity of STX-721 participants with non-small cell lung cancer (NSCLC) harboring EGFR/ HER2 exon 20 insertion mutations (ex20ins).
